Treatment Approaches to IgG4-related Systemic Disease

Arezou Khosroshahi; John H. Stone


Curr Opin Rheumatol. 2011;23(1):67-71. 

In This Article


The natural history of IgG4-RSD in different organs remains incompletely defined. Consensus guidelines for the management of AIP indicate that glucocorticoids are the treatment of choice for remission induction, but neither the optimal glucocorticoid regimen nor the need for maintenance treatment is clear. At present, such decisions must be made on an individual patient basis. Greater appreciation and recognition of IgG4-RSD have led to more frequent diagnoses and the realization that a substantial proportion of patients require consideration of other treatments, either immunosuppressive agents or biologic therapies. Larger studies with prospectively collected patients with a broad spectrum of IgG4-RSD manifestations are required to identify the best approaches to therapy and to address the many unanswered questions in this condition.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: